

RECEIVED 14


JAN 02 2001

C(E)

TECH CENTER 1600/2900

PATENT

Attorney Docket No.: 20093-000120US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERALD P. MURPHY et al.

Application No.: 09/016,737

Filed: January 30, 1998

For: ISOLATION AND/OR  
PRESERVATION OF DENDRITIC  
CELLS FOR PROSTATE CANCER  
IMMUNOTHERAPY

Examiner: M. Davis

Art Unit: 1642

AMENDMENT UNDER 37 CFR 1.116

*receiving notice*  
*Box AF*  
*09/22/01*

**Box AF**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed June 21, 2000, please amend this application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

1        23. (Thrice Amended) A composition[,] comprising [: isolated] an increased  
2        number of human dendritic cells [which have been exposed, *in vitro*,] competent and enabled  
3        to activate T cells to a prostate antigen[, wherein said human dendritic cells take up and present  
4        said antigen] as compared to those directly isolated from peripheral blood.

1        28. (Twice Amended) The composition according to claim 23, in which the  
2        dendritic cells[, following exposure *in vitro* to the prostate tissue antigen, wherein said human

*Do not enter*  
*Box AF*  
*06/10/01*